ARCT
Price
$11.03
Change
-$1.12 (-9.22%)
Updated
Oct 30 closing price
Capitalization
313.51M
4 days until earnings call
Intraday BUY SELL Signals
BMEA
Price
$0.64
Change
+$0.02 (+3.23%)
Updated
Oct 30 closing price
Capitalization
46.35M
2 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ARCT vs BMEA

ARCT vs BMEA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ARCT vs. BMEA commentary
Nov 02, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a Buy and BMEA is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ARCT with price predictions
Oct 30, 2026

ARCT in downward trend: price dove below 50-day moving average on October 12, 2026

ARCT moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend. In 32 of 34 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The 10-day moving average for ARCT crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 82%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARCT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

The Aroon Indicator for ARCT entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on ARCT as a result. In 72 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.

The Moving Average Convergence Divergence (MACD) for ARCT just turned positive on October 29, 2026. Looking at past instances where ARCT's MACD turned positive, the stock continued to rise in 41 of 49 cases over the following month. The odds of a continued upward trend are 84%.

Following a +8.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARCT advanced for three days, in 229 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

ARCT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.825) is normal, around the industry mean (3.162). P/E Ratio (-3.312) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. P/S Ratio (23.364) is also within normal values, averaging (439.647).

The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. ARCT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARCT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for BMEA with price predictions
Oct 30, 2026

BMEA's RSI Oscillator is sitting in oversold zone for 12 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMEA advanced for three days, in 231 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

BMEA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 14, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BMEA as a result. In 63 of 72 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.

The 10-day moving average for BMEA crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.

The 50-day moving average for BMEA moved below the 200-day moving average on October 29, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMEA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for BMEA entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.819) is normal, around the industry mean (3.162). P/E Ratio (-3.553) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).

The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. BMEA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMEA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
ARCT: Fundamental Ratings
ARCT
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
33
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
38
P/E GROWTH RATING
1..100
96
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ARCTBMEA
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
80%
Momentum
ODDS (%)
Bullish Trend 3 days ago
84%
Bearish Trend 3 days ago
88%
MACD
ODDS (%)
Bullish Trend 3 days ago
84%
N/A
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
89%
Advances
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 5 days ago
85%
Declines
ODDS (%)
Bearish Trend 10 days ago
88%
Bearish Trend 11 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
87%
COMPARISON
Comparison
Nov 02, 2026
Stock price -- (ARCT: $11.03 vs. BMEA: $0.64)
Brand notoriety: ARCT and BMEA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 213% vs. BMEA: 52%
Market capitalization -- ARCT: $313.51M vs. BMEA: $46.35M
ARCT [@Biotechnology] is valued at $313.51M. BMEA’s [@Biotechnology] market capitalization is $46.35M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $141.65B. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 1 FA rating(s) are green while BMEA’s FA Score has 1 green FA rating(s).

  • ARCT’s FA Score: 1 green, 4 red.
  • BMEA’s FA Score: 1 green, 4 red.
According to our system of comparison, ARCT is a better buy in the long-term than BMEA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 4 TA indicator(s) are bullish while BMEA’s TA Score has 4 bullish TA indicator(s).

  • ARCT’s TA Score: 4 bullish, 5 bearish.
  • BMEA’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both ARCT and BMEA are a bad buy in the short-term.

Price Growth

ARCT (@Biotechnology) experienced а +12.09% price change this week, while BMEA (@Biotechnology) price change was +6.57% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.20%. For the same industry, the average monthly price growth was -14.01%, and the average quarterly price growth was -15.33%.

Reported Earning Dates

ARCT is expected to report earnings on Nov 05, 2026.

BMEA is expected to report earnings on Nov 03, 2026.

Industries' Descriptions

@Biotechnology (+0.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ARCT
Daily Signal:
Gain/Loss:
BMEA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

ARCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with ALEC. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then ALEC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARCT
1D Price
Change %
ARCT100%
-9.22%
ALEC - ARCT
60%
Loosely correlated
-1.34%
CRSP - ARCT
51%
Loosely correlated
-5.23%
EDIT - ARCT
50%
Loosely correlated
-8.87%
AXON - ARCT
49%
Loosely correlated
-2.35%
RXRX - ARCT
46%
Loosely correlated
-4.95%
More

BMEA and

Correlation & Price change

A.I.dvisor indicates that over the last year, BMEA has been loosely correlated with PROK. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if BMEA jumps, then PROK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BMEA
1D Price
Change %
BMEA100%
+2.68%
PROK - BMEA
38%
Loosely correlated
-11.90%
CAI - BMEA
38%
Loosely correlated
-5.01%
VYGR - BMEA
38%
Loosely correlated
-2.27%
ARCT - BMEA
36%
Loosely correlated
-9.22%
EDIT - BMEA
33%
Loosely correlated
-8.87%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
REPL17.610.22
+1.27%
Replimune Group
CGW64.060.18
+0.28%
Invesco S&P Global Water Index ETF (CGW)
DSAC10.130.01
+0.10%
Daedalus Special Acquisition Corp
EMNT98.840.05
+0.06%
PIMCO Enhanced Short Maturity Active ESG Exchange-Traded Fund (EMNT)
CTM0.49-0.02
-4.00%
Castellum